FDA — authorised 26 April 2022
- Marketing authorisation holder: MYCOVIA PHARMACEUTICALS INC
- Status: approved
🇺🇸 Vivjoa in United States
FDA authorised Vivjoa on 26 April 2022
Marketing authorisations
FDA — authorised 26 April 2022
- Application: NDA215888
- Marketing authorisation holder: MYCOVIA PHARMS
- Local brand name: VIVJOA
- Indication: CAPSULE — ORAL
- Status: approved
Vivjoa in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in United States
Frequently asked questions
Is Vivjoa approved in United States?
Yes. FDA authorised it on 26 April 2022; FDA authorised it on 26 April 2022.
Who is the marketing authorisation holder for Vivjoa in United States?
MYCOVIA PHARMACEUTICALS INC holds the US marketing authorisation.